🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Emmanuella Chinonso Osuala

Centre for the AIDS Programme of Research in South Africa

ORCID: 0000-0002-2035-0935

Also affiliated with University of KwaZulu-Natal

MedicineHealth Professions

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial”.

INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial

BMJ Open(2022)10.1136/bmjopen-2022-067765

N/A

0.484DataRank · unranked

7 citations

Kelly E. Dooley, Kogieleum Naidoo, Nesri Padayatchi, Nonhlanhla Yende‐Zuma, Rubeshan Perumal +4 more

Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study

The Lancet HIV(2025)10.1016/s2352-3018(24)00312-6

N/A

0.315DataRank · unranked

5 citations

Hylke Waalewijn, Kogieleum Naidoo, Marothi Letsoalo, Gabriela Cromhout, Leora Sewnarain +8 more

Fixed-dose combination bictegravir–emtricitabine–tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial

The Lancet HIV(2025)10.1016/s2352-3018(25)00200-0

N/A

0.165DataRank · unranked

2 citations

Kogieleum Naidoo, Marothi Letsoalo, Roeland E. Wasmann, Gillian Dorse, Rubeshan Perumal +33 more

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin

Clinical Infectious Diseases(2025)10.1093/cid/ciaf732

N/A

0DataRank · unranked

0 citations

Ivan Nicholas Nkuhairwe, Marothi Peter Letsoalo, Kogieleum Naidoo, R Perumal, James F Rooney +32 more